C4 Therapeutics, Inc.

General ticker "CCCC" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $323.1M (TTM average)

C4 Therapeutics, Inc. follows the US Stock Market performance with the rate: 5.6%.

Estimated limits based on current volatility of 5.1%: low 1.54$, high 1.70$

Factors to consider:

  • Current price 21.1% below estimated low

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

  • 2024-12-31 to 2025-12-31 estimated range: [2.00$, 5.23$]
  • 2025-12-31 to 2026-12-31 estimated range: [1.41$, 3.81$]

Financial Metrics affecting the CCCC estimates:

  • Negative: Non-GAAP EPS, $ of -1.51 <= 0.04
  • Negative: negative Net income
  • Negative: negative Operating income
  • Positive: Interest expense per share, $ of 0 <= 0
  • Negative: Operating cash flow per share per price, % of -18.39 <= 1.79
  • Negative: Industry operating cash flow per share per price (median), % of -21.10 <= 2.82
  • Negative: Inventory ratio change, % of 8.24 > 1.05
  • Positive: 43.26 < Shareholder equity ratio, % of 61.78 <= 63.75
  • Positive: -0.87 < Investing cash flow per share, $ of -0.74

Similar symbols

Short-term CCCC quotes

2025-03-182025-03-192025-03-202025-03-212025-03-242025-03-252025-03-262025-03-272025-03-282025-03-312025-04-012025-04-022025-04-032025-04-042025-04-072025-04-082025-04-092025-04-102025-04-112025-04-142025-04-152025-04-162025-04-172025-04-212025-04-222025-04-232025-04-242025-04-252025-04-282025-04-291.21.41.61.822.2
Price $

Long-term CCCC plot with estimates

246810Jul 2023Jan 2024Jul 2024Jan 2025Jul 2025Jan 2026Jul 2026Jan 2027−0.4−0.20
CCCCS&P500Health CareNon-GAAP EPS EstimateNon-GAAP EPS ActualPrice $Non-GAAP EPS $

Financial data

YTD 2022-12-31 2023-12-31 2024-12-31
Operating Revenue $31.10MM $20.76MM $35.58MM
Operating Expenses $160.63MM $159.79MM $155.20MM
Operating Income $-129.53MM $-139.03MM $-119.61MM
Non-Operating Income $1.36MM $7.82MM $14.43MM
Interest Expense $2.22MM $1.37MM $0.00MM
R&D Expense $117.84MM $117.71MM $110.64MM
Income(Loss) $-128.18MM $-131.21MM $-105.19MM
Taxes $0.00MM $1.28MM $0.13MM
Profit(Loss)* $-126.50MM $-132.49MM $-105.32MM
Stockholders Equity $289.23MM $246.11MM $215.99MM
Inventory $60.96MM $0.00MM $0.00MM
Assets $430.84MM $376.45MM $349.60MM
Operating Cash Flow $-105.94MM $-106.84MM $-65.16MM
Capital expenditure $5.50MM $1.71MM $0.18MM
Investing Cash Flow $58.42MM $158.35MM $-51.27MM
Financing Cash Flow $1.15MM $45.49MM $45.34MM
Earnings Per Share** $-2.59 $-2.67 $-1.52

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.